Good morning, everyone, and how are you today? Once again, we are enduring a hectic morning on the Pharmalot corporate campus as we try to hustle assorted short people off to their respective school houses. So much to do and so little time. However, there is always time for a cup of stimulation. So please indulge us while we quaffe another mug of Southern Pecan, our antidote to assorted distractions. Meanwhile, here are some tidbits to help you jumpstart your own day. Hope all goes well and drop us a line if you hear something interesting. Have a good one...
Failed J&J/Pfizer Alzheimer Drug Hit Biomarker Target (Reuters)
Merck Insomnia Drug Shows Positive Results (MarketWatch)
In Canada, Insurers Are Pushing For More Generics (National Post)
Geron Ends Study Of Breast Cancer Drug (Wall Street Journal)
Testosterone Marketing Is Pumped Up, Despite Safety Concerns (Associated Press)
FDA Fast Tracks Flesh-Eating Bacteria Treatment (Reuters)
AstraZeneca and WuXi In Joint Venture (Bloomberg News)
Novartis Argues For Gleevec Patent In Indian Court (Reuters)
Amarin Awaits Market Exclusivity On Heart Drug (The Street)
Hay Fever Vaccine Shows Early Promise (BBC News)
Health Canada Silent On Plant Inspections (CTV News)
EDITOR'S NOTE: Please check this post for updates
tea kettle thx to mirahartford on flickr
4 Comments
...or that the biomarkers are bullshit. As usual.
"One small step for man...."